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Induction of labour, once considered a practice to be avoided unless absolutely necessary, is 
becoming increasingly common. Many different methods of induction of labour, ranging from mechanical 
to pharmacological, are available and when used in various combinations and sequences, offer an 
overwhelming number of possibilities. With misoprostol being one of the most common and efficacious 
labour induction agents, the quest to optimise the route and dosing of the drug are important. Misoprostol 
is included on the World Health Organization's list of essential medicines and can be administered by 
many routes and dosing regimens (World Health Organization Who Tech Rep Ser 2015;994:1–546; Elati 
et al. BJOG 2009;116:61–9). The optimal dosing and route of delivery remain undecided.  
When a clearly superior drug strategy eludes providers, new technologies and products can be 
tempting as they seem to present a logical, optimal solution to drug dilemmas. Nevertheless, these new 
strategies or products must be tested. Wallströom et al. (BJOG 2019;126:1148‐55) compare a slow‐
release misoprostol vaginal insert (MVI) with the WHO recommended dose of oral misoprostol in a 
randomised controlled trial. The authors did an excellent job of examining the many factors that 
determine a superior labour induction agent, including time to delivery, caesarean delivery rate, adverse 
maternal and neonatal outcomes, and patient satisfaction. The trial was well planned to have as low a risk 
of bias as possible. Typical to many labour induction studies involving different routes of drug, the 
authors did not blind the interventions by using a placebo for the alternative routes. The analytical 
methods, including censoring women who underwent a caesarean, were appropriate.  
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Comparing oral misoprostol solution to the MVI, the authors found no difference in time from 
induction to vaginal delivery (median 23.2 versus 21.1 hours, P = 0.31), vaginal delivery within 24 hours 
(50.5% versus 55.7%, P = 0.16), or rate of caesarean delivery (31.9% versus 26.6%, P = 0.09). 
Comparing oral misoprostol solution to the MVI, the authors found no difference in time from induction 
to delivery (median 23.2 versus 21.1 hours P = 0.31), vaginal delivery within 24 hours (50.5% versus 
55.7%, P = 0.16), or rate of caesarean delivery (31.9% versus 26.6%, P = 0.09). MVI not only failed to 
show improvement over oral misoprostol solution in delivery outcomes, but also the MVI group was 
found to incur more adverse events. A higher proportion of women in the MVI group developed 
hyperstimulation necessitating tocolytics (4.0% for oral versus 22.7% for MVI, P < 0.01). Women in both 
groups had similarly high rates of satisfaction with their delivery experience (P = 0.55).  
When two interventions may be clinically equivalent and satisfaction with the methods are also 
equivalent, the cost of each intervention can be weighed into the clinical decision‐making. The authors 
presented the cost of each therapy in the Methods but did not discuss the implications in the Results or 
Discussion. Women in the oral misoprostol group received an average of 5.5 doses, which calculates to a 
mean total cost of 13.75 SEK. Each MVI costs ‘about 1000 SEK’. Hence, the women receiving an MVI 
would incur more than 70 times the drug cost compared with those receiving oral administration. Given 
the lack of difference in efficacy and the potential increased adverse effects and cost with MVI, the 
authors reach the conclusion that oral misoprostol remains the first‐line recommendation. 
Although this study has its limitations, including being limited to nulliparous low‐risk women, it 
was well executed. This trial highlights the need to rigorously test new medications and technologies, 
something the authors accomplished. Comparing the efficacy, safety and cost data, and synthesising trials 
systematically can lead us closer to an optimal strategy for labour induction (Alfirevic et al. BJOG 
2016;123:1462–70).  
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